Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Sayako Yuda"'
Publikováno v:
Clinical Hematology International, Vol 4, Iss 3, Pp 89-98 (2022)
Abstract Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While sev
Externí odkaz:
https://doaj.org/article/d572872d626945c5b4cfd7ae41e7a6fa
Autor:
Erika Hiraga, Takuo Yamai, Kenji Ikezawa, Yasuharu Kawamoto, Takeru Hirao, Sena Higashi, Makiko Urabe, Yugo Kai, Ryoji Takada, Tasuku Nakabori, Hiroyuki Uehara, Ayumi Ryu, Sayako Yuda, Keichiro Honma, Kazuyoshi Ohkawa
Publikováno v:
Clinical Case Reports, Vol 11, Iss 4, Pp n/a-n/a (2023)
Abstract This report highlights the importance of considering multiple myeloma in the differential diagnosis of a pancreatic tumor with bone lesions. sampling not only from the pancreatic lesion but also from bone lesions may reach an accurate diagno
Externí odkaz:
https://doaj.org/article/cd1495c8eed54378979aa8e829c58fac
Autor:
Takahiro Fujino, Dai Maruyama, Akiko‐Miyagi Maeshima, Yo Saito, Hanae Ida, Rika Hosoba, Sayako Yuda, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Junya Kuroda, Koji Izutsu
Publikováno v:
Cancer Medicine, Vol 11, Iss 10, Pp 2106-2116 (2022)
Abstract Watchful waiting (WW) is one of the standard approaches for newly diagnosed follicular lymphoma (FL) patients with low‐tumor burden. However, the impact of WW in FL patients at the first progression, remains unclear. We reviewed 206 FL pat
Externí odkaz:
https://doaj.org/article/b0e85bf5f2b24759b9f9076d79d6f745
Autor:
Tomotaka Suzuki, Dai Maruyama, Akiko Miyagi‐Maeshima, Junko Nomoto, Kinuko Tajima, Yuta Ito, Shunsuke Hatta, Sayako Yuda, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Hirokazu Taniguchi, Koji Izutsu, Yukio Kobayashi, Kensei Tobinai
Publikováno v:
Cancer Medicine, Vol 10, Iss 15, Pp 5101-5109 (2021)
Abstract Background Approximately 15% of patients with diffuse large B‐cell lymphoma (DLBCL) experience refractory or early relapsed disease after initial rituximab‐containing chemoimmunotherapy is regarded as a primary refractory disease. Althou
Externí odkaz:
https://doaj.org/article/6c9fedcd3a36413f9569e5dd522429e1
Autor:
Ritsuko Nakai, Suguru Fukuhara, Akiko Miyagi Maeshima, Sung‐Won Kim, Yuta Ito, Shunsuke Hatta, Tomotaka Suzuki, Sayako Yuda, Shinichi Makita, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Koji Izutsu
Publikováno v:
Clinical Case Reports, Vol 7, Iss 12, Pp 2500-2504 (2019)
Abstract This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.
Externí odkaz:
https://doaj.org/article/1146156fd4824a3ea995b07729d80109
Autor:
Tomotaka Suzuki, Suguru Fukuhara, Junko Nomoto, Satoshi Yamashita, Akiko (Miyagi) Maeshima, Yuta Ito, Shunsuke Hatta, Sayako Yuda, Shinichi Makita, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Hirokazu Taniguchi, Toshikazu Ushijima, Koji Izutsu, Kensei Tobinai, Yukio Kobayashi
Publikováno v:
Haematologica, Vol 106, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/bb772a9973344ea0b635b99953e40fb4
Autor:
Suguru Fukuhara, Koji Izutsu, Wataru Munakata, Junko Nomoto, Akiko Miyagi-Maeshima, Shinichi Makita, Yuta Ito, Shunsuke Hatta, Dai Maruyama, Sayako Yuda, Hirokazu Taniguchi, Kinuko Tajima, Yukio Kobayashi, Kensei Tobinai, Tatsuya Suzuki, Tomotaka Suzuki
Publikováno v:
Cancer Medicine, Vol 10, Iss 15, Pp 5101-5109 (2021)
Cancer Medicine
Cancer Medicine
Background Approximately 15% of patients with diffuse large B‐cell lymphoma (DLBCL) experience refractory or early relapsed disease after initial rituximab‐containing chemoimmunotherapy is regarded as a primary refractory disease. Although the st
Autor:
Hirokazu Taniguchi, Tatsuya Suzuki, Sayako Yuda, Wataru Munakata, Suguru Fukuhara, Koji Izutsu, Rika Hosoba, Yo Saito, Shinichi Makita, Akiko Miyagi Maeshima, Hanae Ida, Dai Maruyama, Takahiro Fujino
Publikováno v:
Human Pathology. 102:33-43
Summary Diffuse large B-cell lymphoma (DLBCL) is the most common histological transformation (HT) of follicular lymphoma (FL). Other types of HT are very rare, and their incidence, histopathology, and patient outcomes have not been sufficiently descr
Autor:
Sung-Won Kim, Suguru Fukuhara, Shinichi Makita, Koji Izutsu, Yuta Ito, Dai Maruyama, Akiko Miyagi Maeshima, Ritsuko Nakai, Sayako Yuda, Wataru Munakata, Tatsuya Suzuki, Tomotaka Suzuki, Shunsuke Hatta
Publikováno v:
Clinical Case Reports
Clinical Case Reports, Vol 7, Iss 12, Pp 2500-2504 (2019)
Clinical Case Reports, Vol 7, Iss 12, Pp 2500-2504 (2019)
This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.
Publikováno v:
Annals of Oncology. 33:S505